Market Overview
Ophthalmic Drugs Market is valued at around USD 41.61 billion in 2022 and is expected to reach USD 66.35 billion by 2033, registering a CAGR of 6.0% over the forecast period. Ophthalmic pharmaceuticals are prescribed for the treatment of a variety of eye-related conditions, such as age-related macular degeneration, cytomegalovirus (CMV), diabetic macular edoema, colour blindness, and diabetic macular edoema (AMD).
These drugs may be administered through contact lenses, emulsions, ointments, aqueous gels, dendrimers, or nanosuspensions. Neomycin, antibiotics, bacitracin, and polymyxin are all used in the production of ophthalmic medications, which help to slow the spread of bacterial infections in the eyes. They are currently offered commercially in three different formulation types: solid, liquid, and semi-solid.
Report Scope
Report Attributes | Description |
Market Size in 2022 (Value) | USD 41,610 million |
Market Forecast in 2033 (Value) | USD 66,350 million |
CAGR % 2023-2031 | 6.0% |
Base Year | 2022 |
Historic Data | 2019-2021 |
Forecast Period | 2023-2033 |
Report USP | Country and regional estimates, key investment areas, companies market share by countries |
Segments Covered | Indication, type, dosage form, sales channel and therapeutic class |
Regional Scope | North America, Europe, APAC, South America and Middle East and Africa |
Country Scope | U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Key Companies | Santen Pharmaceutical, Valeant Pharmaceuticals, Shire, Novartis, Genentech, Allergan, Sun Pharmaceutical Industries, Actavis Generics, Regeneron Pharmaceuticals, Pfizer, Johnson and Johnson, Bausch and Lomb, and others. |
The Ophthalmic Drugs Market - Growth Factor
The demand is expected to increase as a result of rising research and development efforts to create and introduce novel ophthalmic medications, as well as a number of strategic initiatives anticipated by the major players. Additionally, the market for ophthalmic medications is projected to rise as a result of unmet needs in ophthalmology. Nearly 2.2 billion people are predicted to have distant or near vision impairment disorders, and of these, at least half, or 1 billion instances, can be avoided with the aid of adequate treatment, according to the World Health Organization's October 2021 report on blindness and vision impairment.
High age is the main factor in blindness and vision impairment. The financial burden on the governments is increasing as a result of this high incidence. As a result, the data shows a sharp drop in the amount of money spent treating glaucoma and other ocular conditions. Nevertheless, a surge in the market is projected as a result of the widespread availability of COVID-19 vaccines and the drop in COVID-19 infections. The growth of the ophthalmic medicines market is anticipated to be boosted by major companies' increasing R&D spending and activities.
The Ophthalmic Drugs Market Trends
• The global market for ophthalmic pharmaceuticals is anticipated to be driven by an increase in awareness of the diagnosis and treatment of eye illnesses during the forecast period. Unprecedented market dynamics are occurring, and major businesses are putting a lot of effort into R&D initiatives to minimise treatment times.
• They are introducing cutting-edge delivery systems that offer gradual, dependable, and sustained release to treat glaucoma patients' intraocular pressure.
• To fill unmet needs in the market, such as inherited retinal diseases, emerging businesses are concentrating on developing small molecule biological medicines for specialised combinational therapy.
• During the projected period, this is anticipated to increase treatment penetration and compliance, driving up the market for ophthalmic medications worldwide.
The Ophthalmic Drugs Market – Segmentation
The Ophthalmic Drugs Market fragrance concentrates market has been sub-classified into indication, type, dosage form, distribution channel, therapeutic class.
Prescription ophthalmic drugs are medications that require a prescription from a licensed healthcare provider to be dispensed. These drugs are used to treat various eye diseases and conditions, including glaucoma, dry eye syndrome, uveitis, and macular degeneration, among others.
The demand for prescription ophthalmic drugs has been growing due to the increasing prevalence of eye diseases and disorders, the aging population, and the availability of advanced ophthalmic drug delivery systems. These factors have led to a rise in the number of people seeking medical attention for their eye conditions, resulting in an increase in the demand for prescription ophthalmic drugs.
In addition, the introduction of new drugs with improved efficacy and safety profiles has also contributed to the growth of the prescription ophthalmic drugs market. For instance, the introduction of anti-VEGF drugs for the treatment of macular degeneration has significantly improved patient outcomes and led to an increase in the demand for prescription ophthalmic drugs.
The market for prescription ophthalmic drugs is expected to continue to grow in the coming years, driven by factors such as the increasing incidence of eye diseases, rising healthcare expenditures, and advancements in drug delivery technologies.
Solid ophthalmic drug forms, such as tablets and capsules, are gaining popularity in the ophthalmic drug market due to several advantages over traditional liquid and suspension formulations. These solid dosage forms are easy to administer and provide more precise dosing, reducing the risk of over or under medication. They also have a longer shelf life and are more stable than liquid forms.
The demand for solid ophthalmic drug forms is increasing due to the convenience they offer to patients, especially those with mobility or dexterity issues. The availability of innovative drug delivery systems such as ocular inserts and sustained-release implants has further driven the demand for solid ophthalmic drug forms.
In addition, the development of new drugs with improved efficacy and safety profiles in solid forms has also contributed to the growth of the market. For instance, some of the drugs used in the treatment of age-related macular degeneration are available in tablet or capsule form, providing a more convenient option for patients.
The market for solid ophthalmic drug forms is expected to continue to grow in the coming years, driven by factors such as increasing prevalence of eye diseases, rising demand for convenient drug delivery systems, and advancements in drug development and manufacturing technologies.
Market Regional Analysis
North America dominated the global Ophthalmic Drugs Market, due to increased awareness of eye disorders, the presence of a strong healthcare infrastructure, and major players like Pfizer, Inc. and Alcon in the area, the market is predicted to develop at the greatest CAGR.
India has a high demand for ophthalmic drugs due to the increasing prevalence of eye diseases, a large population, and improving healthcare infrastructure. The country has a high burden of diseases such as cataract, glaucoma, and diabetic retinopathy, which require the use of ophthalmic drugs for treatment.
The Indian ophthalmic drugs market is primarily driven by the rising incidence of eye diseases, increasing awareness about eye health, and a growing geriatric population. The demand for ophthalmic drugs in India is also driven by the increasing availability of affordable drugs and the expansion of healthcare facilities in rural areas.
The Indian ophthalmic drugs market is dominated by domestic players, who account for a significant share of the market. However, international players are also entering the market, attracted by the growth potential offered by the Indian market.
The Indian government has taken several initiatives to improve eye health in the country, including the implementation of national programs for the prevention and control of blindness and visual impairment. These initiatives are expected to further boost the demand for ophthalmic drugs in India in the coming years.
Japan has a high demand for ophthalmic drugs due to a large elderly population, high prevalence of eye diseases, and advanced healthcare infrastructure. The country has a high burden of diseases such as age-related macular degeneration, glaucoma, and diabetic retinopathy, which require the use of ophthalmic drugs for treatment.
The Japanese ophthalmic drugs market is primarily driven by the increasing incidence of eye diseases, a growing geriatric population, and increasing healthcare expenditure. The demand for ophthalmic drugs in Japan is also driven by the introduction of new drugs with improved efficacy and safety profiles, such as anti-VEGF drugs used in the treatment of macular degeneration.
The Japanese market for ophthalmic drugs is highly competitive, with several domestic and international players operating in the market. The market is dominated by local players, who account for a significant share of the market. However, international players are also present, attracted by the growth potential offered by the Japanese market.
The Japanese government has taken several initiatives to improve eye health in the country, including the introduction of a national screening program for glaucoma and the implementation of measures to prevent diabetic retinopathy. These initiatives are expected to further boost the demand for ophthalmic drugs in Japan in the coming years.
The Ophthalmic Drugs Market – Competitive Landscape
Novartis AG: Novartis has a strong presence in the ophthalmic drugs market, with drugs such as Lucentis and Xiidra. The company's strategy involves investing in research and development to develop new drugs and expanding its geographic presence through partnerships and acquisitions.
Allergan, Inc.: Allergan is a leading player in the ophthalmic drugs market, with drugs such as Restasis and Ozurdex. The company's strategy involves focusing on innovation and developing new drugs to address unmet medical needs. It also aims to expand its global presence through strategic partnerships and acquisitions.
Pfizer Inc.: Pfizer has a strong presence in the ophthalmic drugs market, with drugs such as Xalatan and Eylea. The company's strategy involves investing in research and development to develop new drugs and expanding its presence in emerging markets through partnerships and acquisitions.
Roche Holding AG: Roche is a major player in the ophthalmic drugs market, with drugs such as Lucentis and Avastin. The company's strategy involves investing in research and development to develop new drugs and expanding its geographic presence through partnerships and acquisitions.
Bayer AG: Bayer has a significant presence in the ophthalmic drugs market, with drugs such as Eylea and Visudyne. The company's strategy involves investing in research and development to develop new drugs and expanding its presence in emerging markets through partnerships and acquisitions.
Overall, the top companies in the ophthalmic drugs market are focusing on innovation and research and development to develop new drugs and expand their geographic presence through partnerships and acquisitions. They are also targeting emerging markets for growth opportunities.
By Indication
• Dry eye
• Glaucoma
• Infection/inflammation/allergy
• Retinal disorders- wet age-related macular degeneration. Dry age-related macular degeneration, diabetic retinopathy
• others
By Type
• prescription drugs
• over-the-counter drugs
• others
By Dosage Form
• liquid ophthalmic drug forms
• solid ophthalmic drug forms
• semisolid ophthalmic drug forms
• multicompartment drug delivery system
• other ophthalmic drug forms
• others
By Sales Channel
• hospital pharmacies
• drug store
• online pharmacies
• others
By Therapeutic class
• anti-glaucoma
• anti-infection
• anti-inflammation
• anti-allergy
• others
Companies
Santen Pharmaceutical
Valeant Pharmaceuticals
Shire
Novartis
Genentech
Allergan
Sun Pharmaceutical Industries
Actavis Generics
Regeneron Pharmaceuticals
Pfizer
Johnson and Johnson
Bausch and Lomb
Others.
By Region
· North America
o U.S.
o Canada
o Mexico
· Europe
o Germany
o France
o UK
o Italy
o Spain
o Russia
o Rest of Europe
· Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o ASEAN
o Rest of APAC
· South America
o Brazil
o Argentina
o Chile
o Rest of South America
· Middle East and Africa
o Saudi Arabia
o UAE
o South Africa
o Rest of MEA
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
The Ophthalmic Drugs Market is valued at around USD 41.61 billion in 2022 and is expected to reach USD 66.35 billion by 2033, registering a CAGR of 6.0% over the forecast period.
The global market for ophthalmic pharmaceuticals is anticipated to be driven by an increase in awareness of the diagnosis and treatment of eye illnesses during the forecast period.
Some of the major players operating within the market are Santen Pharmaceutical, Valeant Pharmaceuticals, Shire, Novartis, Genentech, Allergan, Sun Pharmaceutical Industries, Actavis Generics, Regeneron Pharmaceuticals, Pfizer, Johnson and Johnson, Bausch and Lomb, and others.
North America dominated the global Ophthalmic Drugs Market, due to increased awareness of eye disorders, the presence of a strong healthcare infrastructure, and major players like Pfizer, Inc. and Alcon in the area, the market is predicted to develop at the greatest CAGR.
}})
Only Four Thousand Seven Hundred Fifty US dollar
Only Five Thousand Seven Hundred Fifty US dollar
Only Seven Thousand Seven Hundred Fifty US dollar